Third Rock’s Barbara Weber Appointed CEO of Tango Therapeutics

Barbara Weber, the Third Rock Ventures partner who has been serving as interim CEO of Tango Therapeutics, is now formally the company’s chief executive. Weber will also continue as a partner at Third Rock, the venture capital firm that incubated the cancer drug developer. Cambridge, MA-based Tango spun out of Third Rock in March, backed by a $55 million Series A investment round. Before joining Third Rock, Weber held senior leadership positions in oncology research at Novartis (NYSE: [[ticker:NVS]]) and GlaxoSmithKline (NYSE: [[ticker:GSK]]).

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.